StockUS listing USKSPHFPINKHealthcareDefensive Anchor

Kissei Pharmaceutical Co. Ltd(KSPHF) Stock Analysis | Healthcare

USD --+0.00%
Reward60Moderate
Risk25Low
75%Data
3.0% dividend yield · Revenue growing 16% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.19Bn
Reward Ratingⓘ60 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ25 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KSPHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kissei Pharmaceutical Co. Ltd?

researches, develops, manufactures, and sells pharmaceutical products primarily in Japan.

AI Brief Pro

The brief on Kissei Pharmaceutical Co. Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Kissei Pharmaceutical Co. Ltd?

researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.19B, and a P/E ratio of 12.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (60)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio12.2036
Beta-0.259
Insider Activity
12M windowNo data
No insider activity data available for this ticker.